New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Check below for free stories on JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 15, 2014
08:54 EDTJNJJ&J CEO says confident about long term growth prospects of healthcare market
Subscribe for More Information
08:25 EDTJNJJohnson & Johnson says innovation sustaining long-term growth
Says MD&D progressing well towards 30 major filings by 2017. In Pharmaceuticals, sees 10 new products and 25 significant line extensions planned by 2017. Sees ~4.5% CAGR expected for WW prescription drug sales through 2017, despite potential headwinds. Comments from slides that will be presented on the Q2 earnings conference call.
07:49 EDTJNJJohnson & Johnson reports Q2 Worldwide Pharmaceutical sales of $8.5B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson raises FY14 EPS to $5.85-$5.92 from $5.75-$5.85
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales up 14.9% to $9.13B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 EPS excluding items $1.66, consensus $1.55
Subscribe for More Information
07:15 EDTKOIIR Holdings to hold a conference
14th Annual Shopper Insights in Action Conference to be held in Chicago on July 14-16.
06:49 EDTCMAComerica reports Q2 EPS 80c, consensus 76c
Subscribe for More Information
July 14, 2014
15:24 EDTWABC, CMA, JNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
10:00 EDTSCHWOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Ardelyx (ARDX) initiated with a Buy at Citigroup... Century Communities (CCS) initiated with an Overweight at JPMorgan... Charles Schwab (SCHW) initiated with a Buy at Jefferies... Diamondback Energy (FANG) initiated with a Neutral at Sterne Agee... E-Trade (ETFC) initiated with a Hold at Jefferies... Foresight Energy (FELP) initiated with an Overweight at Morgan Stanley... Global Logistics Properties (GBTZF) initiated with an Overweight at Barclays... Intercept (ICPT) initiated with a Buy at Deutsche Bank... Jumei (JMEI) initiated with a Buy at BofA/Merrill... MTS Systems (MTSC) initiated with a Buy at Needham... Markit (MRKT) initiated with an Equal Weight at Morgan Stanley... Opus Bank (OPB) initiated with a Buy at CRT Capital... Parnell (PARN) initiated with an Overweight at Piper Jaffray... TD Ameritrade (AMTD) initiated with a Hold at Jefferies... Teradata (TDC) initiated with a Buy at Standpoint Research... Veritiv (VRTV) initiated with an Overweight at Barclays... Viper Energy (VNOM) initiated with a Market Perform at Raymond James... Yelp (YELP) initiated with an Underweight at Evercore... ZS Pharma (ZSPH) initiated with an Outperform at BMO Capital... Zafgen (ZFGN) initiated with an Outperform at Cowen.
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
05:50 EDTSCHWCharles Schwab initiated with a Buy at Jefferies
Subscribe for More Information
July 11, 2014
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
07:26 EDTKOApple, Coke on board with Obama 'SupplierPay' initiative, WSJ says
Subscribe for More Information
July 10, 2014
10:05 EDTCMAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTSCHWCME Group Charles Schwab outlook positive, says Bernstein
Bernstein believes that CME Group (CME) and Charles Schwab (SCHW) should benefit as investors position themselves for interest rates to rise next year.
08:38 EDTCMAComerica upgraded to Buy from Neutral at Guggenheim
Guggenheim upgraded Comerica to Buy given exposure to Texas and California loan growth and asset-sensitivity. Price target raised to $58 from $54.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use